[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-383922-105":59,"doc-detail-383922-en":123},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":116,"head_meta":118,"extra_data":120,"updated_unix":122},105,"en","topical-treatments-for-basal-cell-carcinoma-and-actinic-keratosis-in-the-united-states","Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States","","Skin cancer covers multiple cutaneous malignancies, for which surgical excision is commonly used despite risks and potential adverse effects. Evidence supports topical therapies as a strategy to reduce the need for operative intervention while limiting outcomes such as infection and scarring. Increasing indications, availability, and therapeutic options strengthen their use in dermatology clinics, particularly for basal cell carcinoma (BCC) and actinic keratosis (AK). This review evaluates lesion criteria and topical treatment choices and considers economic and clinical significance moving forward.",{"@graph":69,"@context":115},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/topical-treatments-for-basal-cell-carcinoma-and-actinic-keratosis-in-the-united-states/383922/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/topical-treatments-for-basal-cell-carcinoma-and-actinic-keratosis-in-the-united-states/383922.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109],{"name":110,"@type":111,"acceptedAnswer":112},"How does cost relate to treatment outcomes in the review?","Question",{"text":113,"@type":114},"The review links BCC's growing prevalence and the proportion of excised lesions reported as malignant to treatment cost and outcomes, arguing that topical options can decrease overall expenses and limit in-office procedures.","Answer","https://schema.org",{"og:url":83,"og:type":117,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":119,"canonical":83},"index,follow",{"doc_id":121,"site_id":62},383922,1790386819,{"code":4,"msg":5,"data":124},{"doc_id":121,"user_id":125,"nickname":92,"user_avatar":126,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":127,"file_id":128,"file_url":129,"file_type":130,"file_size":131,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":132,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":133,"faqs":134,"seo_title":135,"seo_description":67,"update_tm":136,"read_time":137},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","cancers   \nReview  \nTopical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States  \nIsabella J. Tan, Gaurav N. Pathak and Frederick H. Silver *  \nCitation: Tan, I.J.; Pathak, G.N.; Silver, F.H. Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States. Cancers 2023, 15, 3927. [https://](https://)[ ](https://)[doi.org/10.3390/cancers15153927](doi.org/10.3390/cancers15153927)  \nAcademic Editor: Jose Manuel Lopes  \nReceived: 5 June 2023  \nRevised: 27 July 2023  \nAccepted: 27 July 2023  \nPublished: 2 August 2023  \nCopyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nDepartment of Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School, Rutgers, The State University of New Jersey, New Brunswick, NJ 08854, USA; [ijt11@rwjms.rutgers.edu](ijt11@rwjms.rutgers.edu) (I.J.T.);  \n[gnp28@rwjms.rutgers.edu](gnp28@rwjms.rutgers.edu) (G.N.P.)  \n* Correspondence: [silverfr@rutgers.edu](silverfr@rutgers.edu)  \nSimple Summary: Basal cell carcinoma and actinic keratosis are two of the most common cutaneous lesions identified in the dermatology clinic. There is established evidence suggesting that topical treatments play a significant role in treating early forms of superficial BCC while also lowering the economic burden of healthcare by alleviating the need for unnecessary biopsies. Considering the expected continued rise in prevalence of BCC and AK in the coming years, topical therapies can decrease the cost of treatment, limit in-office procedures, and lessen the risks associated with surgery, including infection and scarring.  \nAbstract: Skin cancer is an overarching label used to classify a variety of cutaneous malignancies. Surgical excision procedures are the commonly used treatments for these lesions; however, the choice to perform operative intervention may be influenced by other factors. Established research and literature suggest that topical treatments limit the need for surgical intervention and its commonly associated adverse effects, including infection and scarring. In addition, the growing indications for the usage of topical therapies in BCC treatment, as well as their increased availability and therapeutic options, allow for their greater applicability in the dermatology clinic. Certain topical therapies have been highlighted in research, especially those targeting basal cell carcinoma (BCC) and actinic keratosis (AK). There is also a clear correlation between cost and treatment outcomes, considering BCC's ever-growing prevalence and the proportion of excised lesions being reported as malignant. This review will discuss BCC and AK lesion criteria that result in the most successful outcomes using topical treatments, then highlight the various topical treatment options, and finally address their clinical significance moving forward.  \nKeywords: basal cell carcinoma; BCC; actinic keratosis; AK; topical imiquimod; topical fluorouracil; tirbanibulin ointment; BCC treatment  \n1. Introduction  \nBasal cell carcinoma (BCC) is the most common form of skin cancer in the United States, with an estimated 5 .2 million cases in the United States alone [1] . It has been shown that the global incidence of BCC is predicted to continue its growth throughout the next 30 years and, according to current projections, will continue to grow at a rate of 3.6 million new cases annually in the United States alone [2] . Due to the slower growth and relatively lower potential for metastasis of BCC, there is frequent underreporting [3] . There is also a probable underestimation of these statistics. Countries with poor cancer reporting registries are likely to underestimate these figures, inclu","cbCaibfZzOpyBLAe","https://ap.wps.com/l/cbCaibfZzOpyBLAe","pdf",264102,"English","# Introduction\n## Basal cell carcinoma (BCC)\n## Actinic keratosis (AK)\n## Rationale for topical treatment","[{\"question\":\"How does cost relate to treatment outcomes in the review?\",\"answer\":\"The review links BCC's growing prevalence and the proportion of excised lesions reported as malignant to treatment cost and outcomes, arguing that topical options can decrease overall expenses and limit in-office procedures.\"}]","Topical Treatments for Basal Cell Carcinoma and Actinic Keratosis in the United States | PDF",1790260291,25]